Psychiatric comorbid patterns in adults with attention-deficit hyperactivity disorder: Treatment effect and subtypes

Fang-Ju Tsai1,2‡, Wan-Ling Tseng3‡, Li-Kuang Yang1,4, Susan Shur-Fen Gau1,5,6*

1 Department of Psychiatry, National Taiwan University and College of Medicine, Taipei, Taiwan, 2 Department of Psychiatry, En Chu Kong Hospital, New Taipei City, Taiwan, 3 Emotion and Development Branch, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, United States of America, 4 Beitou Branch, Tri-Service General Hospital, National Medical Defense Center, Taipei, Taiwan, 5 Graduate Institute of Brain and Mind Sciences, College of Medicine, National Taiwan University, Taipei, Taiwan, 6 Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan

‡ These authors are co-first authors on this work.
* gaushufe@ntu.edu.tw

Abstract

Psychiatric comorbidities are common in individuals with attention-deficit/hyperactivity disorder (ADHD). In this study, we sought to evaluate the effects of medication and childhood ADHD subtypes on psychiatric comorbidities among adults with ADHD as compared to healthy adult controls. We assessed 121 drug-naïve adults with ADHD, 93 treated adults with ADHD, and 145 healthy controls (age 18–36 years) using semi-structured psychiatric interviews, intelligence tests, and medical records. Drug-naïve adults with ADHD had more comorbidities than treated adults with ADHD and controls. Childhood ADHD-combined subtype, relative to ADHD-inattentive subtype, was associated with higher risks of comorbidities. Current medication treatment was associated with a higher risk for anxiety disorders, and longer treatment duration was associated with lower risks of mood disorders and sleep disorders. Our results indicate that no medication treatment, short treatment duration, and childhood ADHD-combined subtype are associated with increased risks for psychiatric comorbidities among adults with ADHD.

Introduction

Symptoms of childhood attention-deficit/hyperactivity disorder (ADHD) often persist into adulthood among adults with this disorder [1]. The prevalence rate of adult ADHD is estimated at 2.5% based on a meta-analysis [2]. Although a few studies have reported psychiatric comorbidities in adults with ADHD [3, 4], much less is known about differential comorbid patterns in adults with ADHD who have received treatment vs. those who have not [5]. Similarly, data are very limited regarding psychiatric comorbidities in adults with different childhood ADHD subtypes [6, 7].

The existing literature has shown that adults with ADHD, relative to controls, are more likely to have psychiatric disorders [7, 8]. However, to date, only few studies have examined
comprehensively the comorbid patterns within a single study [4, 8, 9]. In addition, some studies only focused on subgroups of adult ADHD such as males [5, 10] and those with major depressive disorder (MDD) [11].

Previous clinical trials have demonstrated the benefits and efficacy of medication in reducing clinical symptoms of ADHD [12] and improving quality of life [13], neuropsychological functions [14], and brain functions [15]. Furthermore, some clinical studies showed that a history of pharmacotherapy for ADHD decreased the risks for oppositional defiant disorder (ODD) [16], substance abuse [17–20], MDD [21], depression [22], or social phobia [23]. Methylphenidate was also found to be associated with causing [24, 25] or treating [24, 25] bulimia nervosa in case reports. However, other studies and case-reports revealed the opposite patterns, reporting that medication may be associated with an increased risk for substance use disorders [26], short-term nicotine use problems [27], and ODD/conduct disorder (CD) [28]. The directionality of these associations remained to be determined, as these relationships may be confounded by ADHD symptom severity and comorbid disorders such as CD [16]. Several follow-up studies show no evidence of stimulant treatment increasing or decreasing the risks for subsequent substance use disorders [29–32], anxiety [28], depression or MDD [28, 33] in children with ADHD when they enter adolescence and adulthood. Given the inconsistent findings regarding treatment effects on comorbidities and the limited research on the effect of treatment duration, more studies are needed.

Research on the associations between ADHD subtypes and psychiatric comorbidities in children and adolescents has suggested differential comorbid patterns [16] and brain functions [34] between ADHD-Combined type (ADHD-C) and ADHD-Inattentive type (ADHD-I), with more comorbid conditions reported in ADHD-C. For example, ADHD-C youths are more likely than ADHD-I youths to have ODD [35], CD [35–39], anxiety disorders [40], generalized anxiety disorder (GAD) [41], MDD [42], bipolar disorder [43, 44], substance use disorder [45, 46], sleep disorders/problems [47, 48], and eating disorders [49]. In contrast, ADHD-I youths have higher risks of anxiety disorders [36, 50] than ADHD-C youths. Adults with ADHD-C are more likely than adults with ADHD-I to have ODD [51], CD [6, 52, 53], panic disorder [52], specific phobia [52], mood disorders [52, 54], MDD [52], bipolar disorder [53], substance use disorders [6, 52, 54], and alcohol use disorder [6, 55]. Regarding sleep problems, sleepiness (greater sleep need) [56] and later circadian preference (evening orientation) [57] are associated with inattentive symptoms in adults with ADHD. However, few studies have investigated the association between childhood ADHD symptoms and adult psychiatric comorbidities [10, 58]. To address this gap, our study also aimed to investigate psychiatric comorbidities in adults with different childhood ADHD subtypes.

Taken together, little is known regarding the effects of medication, the duration of pharmacotherapy, and childhood ADHD subtypes on the psychiatric comorbid patterns in adults with ADHD. Hence, this study aimed to address these gaps in the literature by (1) examining group differences in psychiatric comorbid conditions among drug-naïve adults with ADHD, adults with ADHD treated with medication, and controls; (2) examining the effect of medication duration by comparing drug-naïve adults with ADHD, adults with ADHD treated longer than one year and those treated shorter than one year, and controls, in terms of psychiatric comorbid conditions; and (3) comparing adult psychiatric outcomes among adults with different childhood ADHD subtypes and controls.

**Materials and method**

**Participants**

The sample consisted of 214 adults with a clinical diagnosis of ADHD according to the DSM-IV diagnostic criteria and 145 healthy adult controls aged 18–36 years. Adults with
ADHD were recruited from three sources: (1) a cohort of patients with ADHD assessed during their childhood [20]; (2) patients referred by psychiatrists from out-patient clinics or by family physicians in the National Taiwan University Hospital (NTUH), Taipei, Taiwan, and (3) new patients recruited via advertisements in the community. Our sample was part of a longitudinal follow-up study on ADHD from adolescence to young adulthood which was conducted from January 2011 to December 2015 [20]. The psychiatric interview was conducted from July 2011 to July 2015. To be consistent in the diagnostic criteria used in the diagnosis of ADHD and other psychiatric disorders, we used DSM-IV during the initial assessment (when DSM-5 was not yet available) and the follow-up assessment.

The new patients were screened using the Chinese version of the 6-item Adult ADHD Self-Report Scale-V1.1 [59, 60], followed by a telephone interview by a senior researcher with 10 years of experience in conducting clinical evaluations and psychiatric interviews with patients with ADHD and/or other psychiatric disorders. Potential cases with ADHD were invited for detailed clinical evaluations by the authors (SSG and LKY), followed by the 18-item Conners Adult ADHD Diagnostic Interview [61] by the corresponding author (SSG) for assessing childhood and current diagnosis of ADHD. All the participants were further interviewed by trained research psychologists using the modified adult ADHD supplement [62] of the Chinese version of the Schedule for Affective Disorder and Schizophrenia-Epidemiological Version (K-SADS-E) [63, 64] and SADS [13, 14] for assessing childhood and current diagnosis of ADHD and other psychiatric disorders, respectively. The psychometric property of the Chinese version of the K-SADS-E for DSM-IV was described in details in our previous work [63, 64] and summarized below.

Detailed information about the medication history for treating ADHD (including ever use, current use, duration of use, and daily dosage) and age onset of ADHD were included in the modified adult ADHD supplement of the Chinese K-SADS-E. Both ADHD participants and their parents received psychiatric interviews for the treatment history of medications mentioned above. The treatment data were validated by medical records in the NTUH if available; otherwise, they were validated by Taiwan’s National Health Insurance Claims data, which covers 99.9% of the population in Taiwan. Current use was defined as the presence of medication use for treating ADHD (methylphenidate or atomoxetine) in the past month regardless of the usage history prior to that. Ever use was defined as no medication use for treating ADHD in the past month but the use of these medications prior to the past month. Duration of use was defined as the total number of days on medications.

Adult healthy controls were recruited by advertisements on the internet, newspapers, and flyers at the colleges and public places based on the age and gender distributions of the ADHD group. They were screened by telephone interviews to rule out past or current ADHD symptoms, followed by clinical assessments and psychiatric diagnostic interviews using the Conners Adult ADHD Diagnostic Interview and the adult ADHD supplement of the Chinese K-SADS-E to ensure that they did not have lifetime or current diagnosis of ADHD. They also received the Chinese SADS for assessing other non-ADHD diagnoses.

All participants who had an IQ < 80 ascertained by the Wechsler Adult Intelligence Scale-Revised, had any serious medical illness such as cardiovascular disease, a history of learning disability, psychosis, pervasive development disorder or intellectual disability were excluded from the study.

Procedure

The Research Ethics Committee of National Taiwan University Hospital (approval number, 2010003087R; ClinicalTrials.gov number, NCT01247610) approved this study before its implementation. After detailed explanations of the study, participants who provided written
informed consent were recruited into the study. The final sample included 93 adults with ADHD who had been diagnosed with ADHD during childhood and treated for ADHD (treated ADHD), 121 adults with ADHD who have not been treated for ADHD (drug-naïve ADHD), and 145 adult controls without ADHD.

Measures

The Chinese version of the K-SADS-E. The Chinese K-SADS-E for DSM-IV demonstrated good reliability and validity and had been widely used in a variety of clinical [65–68] and epidemiological [63, 69] studies in Taiwan. The corresponding author modified the ADHD, ODD and CD supplement of the Chinese K-SADS-E for the diagnoses of childhood ADHD, ODD and CD, and current ADHD diagnosis in adults [62, 70, 71]. Its original version, SADS [72, 73], in Chinese has been widely used in psychiatric research for assessing other DSM-IV non-ADHD psychiatric disorders [7, 13, 71].

The Chinese version of the Adult ADHD Self-Report Scale (ASRS). The ASRS, an 18-item self-reported scale, was developed in conjunction with the revision of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). The ASRS consists of two subscales, inattention (9 items) and hyperactivity-impulsivity (9 items), according to the 18 DSM-IV ADHD symptoms criteria. Each item asks how often a symptom occurred during the past six months on a 5-point Likert scale: 0, never; 1, rarely; 2, sometimes; 3, often; 4, very often. The psychometric property of the Chinese ASRS has been established in a sample of 1031 young males from an army base and 3298 young adults from two colleges in northern Taiwan [60]. It is widely used to measure ADHD symptoms in Taiwanese adults [56, 71, 74].

Statistical analysis

Data were analyzed using SAS 9.1 (SAS Institute Inc., Cary, NC, USA). To examine sample characteristics among groups including age, gender, IQ, childhood and adulthood ADHD symptoms, and SES, we conducted chi-square tests (for categorical outcomes) and analyses of variance (ANOVA; for continuous outcomes). We first compared sample characteristics between 214 adults with ADHD (drug-naïve and treated) and 145 healthy controls, and then compared across 3 groups: (1) drug-naïve ADHD (n = 93); (2) treated ADHD (n = 121); and (3) healthy controls (n = 145) (Table 1). When significant group differences were found, post-hoc pairwise comparisons were conducted with corrections by the Scheffe test (Table 1). Descriptive results were displayed as frequencies, percentages, means and standard deviations.

To examine the association between comorbidities and treatment status we compared the three groups (drug-naïve ADHD vs. treated ADHD vs. controls) on comorbid disorders (Table 2). To further determine the effect of treatment duration on comorbidities, we compared the four groups: (1) drug-naïve ADHD; (2) treated ADHD ≤ one year (n = 36); (3) treated ADHD > one year (n = 57); (4) healthy controls (Table 3). We also compared comorbidities among childhood ADHD subtypes: (1) ADHD combined type (ADHD-C, n = 126); (2) ADHD inattentive type (ADHD-I, n = 86); (3) healthy controls (Table 4). Additionally, we conducted multivariate logistic regressions to identify significant predictors (e.g., sex, age onset of ADHD, medication history, ADHD subtypes, IQ for comorbid psychiatric diagnoses (see Table 5). Odds ratios (OR) and 95% confidence intervals (CI) were computed. To address the issue with multiple comparisons among subgroups, we adjusted alpha levels by using the Bonferroni correction method. We divided the alpha level (original alpha less than 0.05 level as significant) by the number of comparisons, i.e., 0.05/n, where n is the number of subgroup comparison. Despite the calculation and presentation of 95% CI in Tables 2, 3 and 4, we only interpreted the results that survived statistical significance with adjusted alpha levels after
Bonferroni correction. For Table 2 and Table 4, the alpha level for significance is 0.05/3 = 0.017; for Table 3, the alpha level for significance is 0.05/6 = 0.008.

## Results

### Sample characteristics

Table 1 presents results of the comparisons between the ADHD and controls, as well as among the three groups. The three-group comparison revealed that drug-naïve ADHD and controls had higher Full-scale IQ, Performance IQ, Verbal IQ (control only) and years of education than treated ADHD. Males were more predominant in treated ADHD than in drug-naïve ADHD and controls. Drug-naïve ADHD had more severe inattentive and hyperactive-impulsive (adulthood only) symptoms during childhood and adulthood than treated ADHD. Because of the between-group differences in age, sex, educational years, and Full-scale IQ, we controlled for these variables in our subsequent analyses.

### Psychiatric comorbid conditions by treatment status

Table 2 displays current psychiatric comorbid conditions for drug-naïve ADHD, treated ADHD, and controls. Drug-naïve ADHD and treated ADHD were more likely than controls...
to have psychiatric disorders including ODD, CD, tic disorder, anxiety disorders (including GAD, specific phobia, social phobia), mood disorders such as dysthymic disorder, substance use disorders (e.g., nicotine use disorder), sleep disorders, and eating disorders. Also, drug-naïve ADHD had a higher likelihood of having MDD, alcohol use disorder, and adjustment disorder than controls. Panic disorder was more prevalent in treated ADHD than controls. Drug-naïve ADHD, compared to treated ADHD, were more likely to have GAD, mood disorders, and adjustment disorders. There were no between-group differences in OCD or bipolar disorders across the ADHD groups and controls.

### Psychiatric comorbid conditions across different childhood ADHD subtypes

Participants with childhood ADHD-C were more likely to have tic disorder, panic disorder, and alcohol use disorder than those with childhood ADHD-I and controls. Moreover,
| Psychiatric diagnoses | 1. Drug-naive ADHD (n = 121) | 2. Treated ADHD ≤ 1 year (n = 36) | 3. Treated ADHD > 1 year (n = 57) | 4. Controls (n = 145) | Odds Ratio (95% CI) or χ² | 1 vs. 4 | 2 vs. 4 | 3 vs. 4 | 1 vs. 2 | 1 vs. 3 | 2 vs. 3 |
|-----------------------|-----------------------------|-----------------------------------|-----------------------------------|-----------------------|---------------------------|--------|--------|--------|--------|--------|--------|
| Oppositional defiant disorder | 60 (49.59) | 16 (44.44) | 30 (52.63) | 2 (1.38) | 71.50 (16.93–301.99) | 57.20 (12.23–267.52) | 79.44 (17.92–352.24) | 1.25 (0.59–2.64) | 0.90 (0.48–1.69) | 0.72 (0.31–1.67) |
| Conduct disorder | 39 (32.23) | 8 (22.22) | 23 (40.35) | 3 (2.07) | 22.79 (6.83–76.09) | 13.52 (3.38–54.15) | 32.02 (9.08–112.88) | 1.69 (0.70–4.04) | 0.71 (0.37–1.37) | 0.42 (0.16–1.09) |
| Tic Disorder | 10 (8.26) | 3 (8.33) | 7 (12.28) | 2 (1.38) | 6.44 (1.38–29.99) | 6.50 (1.04–40.46) | 10.01 (2.01–49.77) | 0.99 (0.26–3.81) | 0.64 (0.23–1.79) | 0.65 (0.16–2.69) |
| Anxiety disorders | 46 (38.02) | 13 (36.11) | 14 (24.56) | 4 (2.67) | 21.62 (7.50–62.37) | 19.92 (5.98–66.43) | 11.48 (3.59–36.70) | 1.09 (0.50–2.35) | 1.88 (0.93–3.82) | 1.74 (0.70–4.31) |
| Generalized anxiety disorder | 23 (19.01) | 3 (8.33) | 2 (3.51) | 0 (0) | < .001 | < .001 | 0.02 | 5.85 (1.47–23.27) | 2.50 (0.40–15.75) |
| Specific phobia | 20 (16.53) | 5 (13.89) | 4 (7.02) | 3 (2.07) | 9.37 (2.71–32.39) | 7.63 (1.73–33.64) | 3.57 (0.77–16.49) | 1.23 (0.43–3.54) | 2.62 (0.83–8.07) | 2.14 (0.53–8.56) |
| Social phobia | 21 (17.36) | 6 (16.67) | 4 (7.02) | 0 (0) | < .001 | < .001 | 0.01 | 1.05 (0.39–2.84) | 2.78 (0.91–8.53) | 2.65 (0.69–10.14) |
| Panic disorder | 3 (2.48) | 1 (2.78) | 4 (7.02) | 0 (0) | 0.57 | 0.044 | 0.01 | 0.89 (0.09–8.83) | 0.34 (0.07–1.56) | 0.38 (0.04–3.53) |
| Obsessive compulsive disorder | 3 (2.48) | 2 (5.56) | 2 (3.51) | 1 (0.69) | 3.66 (0.38–35.66) | 8.47 (0.75–96.16) | 5.24 (0.47–58.91) | 0.43 (0.07–2.69) | 0.70 (0.11–4.31) | 1.62 (0.22–12.03) |
| Mood disorders | 34 (28.10) | 8 (22.22) | 2 (3.51) | 0 (0) | < .001 | < .001 | 0.02 | 1.37 (0.57–3.30) | 10.75 (2.48–46.53) | 7.86 (1.56–39.50) |
| Dysthymic disorder | 23 (19.01) | 7 (19.44) | 1 (1.75) | 0 (0) | < .001 | < .001 | 0.11 | 0.97 (0.38–2.49) | 13.14 (1.73–99.96) | 13.52 (1.59–115.20) |
| Major depression | 10 (8.26) | 1 (2.78) | 1 (1.75) | 0 (0) | < .001 | 0.044 | 0.11 | 3.15 (0.39–25.50) | 5.05 (0.63–40.41) | 1.60 (0.10–26.41) |
| Bipolar disorder | 1 (0.83) | 0 (0) | 0 (0) | 0 (0) | 0.273 | — | — | 0.95 (0.26–3.59) | — | — |
| Substance use disorders | 16 (13.22) | 4 (11.11) | 7 (12.28) | 0 (0) | < .001 | < .001 | 0.01 | 1.18 (0.37–3.79) | 1.09 (0.42–2.81) | 0.92 (0.25–3.41) |
| Nicotine | 16 (13.22) | 4 (11.11) | 7 (12.28) | 0 (0) | < .001 | < .001 | 0.01 | 1.18 (0.37–3.79) | 1.09 (0.42–2.81) | 0.92 (0.25–3.41) |
| Alcohol | 5 (4.13) | 1 (2.78) | 1 (1.75) | 0 (0) | 0.01 | 0.044 | 0.11 | 1.51 (0.17–13.35) | 2.37 (0.27–20.78) | 1.57 (0.10–25.95) |
| Adjustment disorders | 39 (32.23) | 2 (5.56) | 3 (5.26) | 1 (0.69) | 68.49 (9.24–507.77) | 8.47 (0.75–96.16) | 8.00 (0.81–78.58) | 8.09 (1.85–35.38) | 8.56 (2.52–29.10) | 1.06 (0.17–6.67) |
| Sleep disorders | 49 (40.50) | 11 (30.56) | 12 (21.05) | 1 (0.69) | 97.99 (13.26–723.99) | 63.36 (7.83–512.54) | 38.40 (4.86–303.44) | 1.55 (0.70–3.43) | 2.55 (1.23–5.31) | 1.65 (0.64–4.28) |
| Eating disorders | 6 (4.96) | 3 (8.33) | 2 (3.51) | 0 (0) | 0.007 | < .001 | 0.023 | 0.58 (0.14–2.44) | 1.45 (0.28–7.40) | 2.50 (0.40–15.75) |
| Any psychiatric disorder | 106 (87.60) | 25 (69.44) | 39 (68.42) | 11 (7.59) | 86.08 (37.96–195.17) | 27.68 (10.83–70.76) | 26.39 (11.50–60.56) | 3.11 (1.28–7.59) | 3.26 (1.50–7.10) | 1.05 (0.43–2.59) |

ADHD, attention-deficit/hyperactivity disorder; CI, confidence interval

* Fisher exact p value.

https://doi.org/10.1371/journal.pone.0211873.t003

PLOS ONE | https://doi.org/10.1371/journal.pone.0211873 February 7, 2019 7 / 16
participants with childhood ADHD-C were more likely to have eating disorder than controls and more likely to have ODD, CD, and sleep disorders than childhood ADHD-I (Table 4).

The psychiatric comorbid patterns across different ADHD subtypes at the current assessment (adult ADHD subtypes) are presented in S1 Table. In general, both ADHD subtypes were more likely to have all psychiatric comorbid conditions assessed herein than controls except bipolar disorder. Adults with ADHD-C adults were more likely to have lifetime ODD, CD, and sleep disorders than adults with ADHD-I.

**Table 4. Psychiatric comorbid conditions among childhood ADHD subtypes*.**

| Psychiatric diagnoses            | Combined type (n = 126) | Inattention type (n = 86) | Controls (n = 145) | Combined type vs. Controls | Inattention type vs. Controls | Combined type vs. Inattention type |
|---------------------------------|------------------------|---------------------------|--------------------|---------------------------|------------------------------|-----------------------------------|
| N (%)                           | N (%)                  | N (%)                    |                    |                           |                              |                                   |
| Oppositional defiant disorder   | 81 (64.29)             | 24 (27.91)                | 2 (1.38)           | 131.63 (31.09–557.23)     | 27.68 (6.35–120.73)          | 4.76 (2.62–8.64)                 |
| Conduct disorder                | 60 (47.62)             | 9 (10.47)                 | 3 (2.07)           | 43.69 (13.21–144.49)      | 5.53 (1.46–21.04)            | 7.90 (3.64–17.13)                |
| Tic Disorder                    | 17 (13.49)             | 3 (3.49)                  | 2 (1.38)           | 11.15 (2.52–49.28)        | 2.58 (0.42–15.78)            | 4.32 (1.22–15.21)                |
| Anxiety disorders               | 48 (38.10)             | 25 (29.07)                | 4 (2.76)           | 21.69 (7.54–62.41)        | 14.45 (4.82–43.29)           | 1.50 (0.83–2.70)                 |
| Generalized anxiety disorder    | 18 (14.29)             | 10 (11.63)                | 0 (0)              | < .001*                   | < .001*                      | 1.27 (0.55–2.90)                 |
| Specific phobia                 | 20 (15.87)             | 9 (10.47)                 | 3 (2.07)           | 8.93 (2.59–30.84)         | 5.53 (1.46–21.04)            | 1.61 (0.70–3.74)                 |
| Social phobia                   | 20 (15.87)             | 11 (12.79)                | 0 (0)              | < .001*                   | < .001*                      | 1.29 (0.58–2.84)                 |
| Panic disorder                  | 6 (4.76)               | 2 (23.3)                  | 0 (0)              | .008*                     | .065*                        | 2.10 (0.41–10.66)                |
| Obsessive compulsive disorder   | 7 (5.6)                | 0 (0)                     | 1 (0.69)           | 8.47 (1.03–69.82)         | .440*                        | .026*                            |
| Mood disorders                  | 28 (22.2)              | 16 (18.60)                | 0 (0)              | < .001*                   | < .001*                      | 1.25 (0.63–2.48)                 |
| Dysthymic disorder              | 22 (17.46)             | 9 (10.47)                 | 0 (0)              | < .001*                   | < .001*                      | 1.81 (0.79–4.15)                 |
| Major depression                | 5 (3.97)               | 7 (8.14)                  | 0 (0)              | .016*                     | < .001*                      | 0.47 (0.14–1.52)                 |
| Bipolar disorder                | 1 (0.79)               | 0 (0)                     | 0 (0)              | .283*                     | —                            | .408*                            |
| Substance use disorders         | 20 (15.87)             | 7 (8.14)                  | 0 (0)              | < .001*                   | < .001*                      | 2.15 (0.87–5.33)                 |
| Nicotine                        | 20 (15.87)             | 7 (8.14)                  | 0 (0)              | < .001*                   | < .001*                      | 2.15 (0.87–5.33)                 |
| Alcohol                         | 7 (5.6)                | 0 (0)                     | 0 (0)              | .004*                     | —                            | .026*                            |
| Adjustment disorders            | 28 (22.2)              | 16 (18.60)                | 1 (0.69)           | 41.14 (5.51–307.40)       | 32.91 (4.28–253.22)          | 1.25 (0.63–2.48)                 |
| Sleep disorders                 | 56 (44.44)             | 16 (18.60)                | 1 (0.69)           | 115.19 (15.62–849.29)     | 32.91 (4.28–253.18)          | 3.50 (1.83–6.68)                 |
| Eating disorders                | 9 (7.14)               | 2 (2.33)                  | 0 (0)              | .001*                     | .065*                        | 3.26 (0.69–15.47)                |
| Any psychiatric disorder        | 114 (90.48)            | 54 (62.79)                | 11 (7.59)          | 115.71 (49.19–272.19)     | 20.56 (9.67–43.70)           | 5.63 (2.69–11.78)                |

ADHD, attention-deficit/hyperactivity disorder; CI, confidence interval

* two cases of ADHD, hyperactivity-impulsivity subtype, were excluded from the analysis

* Fisher exact p value.

https://doi.org/10.1371/journal.pone.0211873.t004

**Associated factors of comorbid psychiatric disorders**

Multivariate analyses revealed that childhood ADHD-C was associated with a higher risk of ODD, CD, and sleep disorders. Current use of medication was associated with a higher risk of anxiety disorders. Longer duration of medication use was associated with lower risks of mood disorders and sleep disorders (Table 5). Univariate analyses demonstrated similar results (S2 Table).

**Discussion**

The current study is one of the few studies that examined comprehensively the psychiatric comorbid patterns in adults with ADHD with regards to the effects of treatment history and
duration, as well as childhood ADHD subtypes. We found that adults with ADHD, in general, had significantly more comorbid psychiatric conditions than controls. Drug-naïve adults with ADHD, relative to treated ADHD and controls, had more core ADHD symptoms during childhood and adulthood (except for childhood hyperactivity/impulsivity) and more psychiatric comorbidities, particularly GAD, mood disorders, adjustment disorders, and sleep disorders. Childhood ADHD-C subtype, relative to ADHD-I, was associated with higher risks of ODD, CD, OCD, alcohol use disorder, and sleep disorders. Importantly, we found that childhood ADHD-C was a strong correlate of several common comorbid conditions including ODD, CD, and sleep disorders. Current use of medication and a shorter duration of medication use were associated with anxiety and mood disorders, respectively.

Similar to our adolescent ADHD study [20] and previous adult ADHD studies [7], we found that adults with ADHD were more likely to have comorbid psychiatric conditions. High rates of comorbid conditions were present in both drug-naïve ADHD or treated ADHD, regardless of ADHD subtypes and comorbid conditions such as ODD [4, 10], CD [4, 75], tic disorder [4], anxiety disorders [4, 9], GAD [3, 4, 9], specific phobia [4, 9], social phobia [4, 8, 9], mood disorders [4, 8, 9], dysthymic disorder [9, 51], substance use disorders [3, 8, 9, 55, 75], nicotine use disorder [75], sleep disorders [56], and eating disorders [4, 55]. Moreover, our findings of only drug-naïve adult ADHD but not treated adult ADHD having increased risks for MDD and alcohol use disorder provide evidence to support that treatment with medication may offset the occurrence of MDD [3, 4, 8, 9, 11, 55] and alcohol use disorder [8, 51].

No studies have examined the association between treatment effects and panic disorder or specific phobia in adults with ADHD. Our result contributes to the literature by showing that panic disorder was more prevalent in treated ADHD adults than controls. Whether this finding is due to treatment-induced panic-like side effects requires further clarification from future research. Another novel finding is that specific phobia was more prevalent in drug-naïve ADHD and ADHD-TS than controls, suggesting that long-term treatment (> one year), relative to no treatment or short-term treatment (≤ one year), was associated with a decreased risk of specific phobia in adults with ADHD. A prospective follow-up study of these patients is warranted to test the causal effect i.e., whether longer treatment duration indeed decreases the risk of specific phobia.

Previous studies reported that patients with ADHD treated for at least one year did not differ from drug-naïve ADHD in the risk of MDD [33] and that adults with ADHD treated for

**Table 5. Multivariate analysis.**

|                          | Oppositional defiant disorder | Conduct disorder | Anxiety disorders | Mood disorders | Sleep disorders |
|--------------------------|------------------------------|-----------------|-----------------|---------------|----------------|
| Sex                      | 1.39 (0.71–2.71)             | 1.22 (0.57–2.60) | 0.52 (0.27–1.01) | 0.90 (0.42–1.91) | 0.90 (0.45–1.79) |
| Age of onset             | 0.92 (0.78–1.09)             | 0.91 (0.75–1.12) | 0.96 (0.84–1.09) | 1.04 (0.90–1.19) | 1.04 (0.93–1.16) |
| Age of treatment         | 1.00 (0.95–1.04)             | 0.97 (0.92–1.02) | 1.00 (0.95–1.04) | 1.01 (0.96–1.07) | 1.00 (0.95–1.05) |
| Medication history       |                              |                 |                 |               |                |
| Ever use                 | 1.33 (0.47–3.72)             | 0.73 (0.24–2.19) | 0.43 (0.14–1.32) | 2.35 (0.64–8.64) | 0.73 (0.26–2.08) |
| Current use              | 0.64 (0.26–1.56)             | 0.67 (0.26–1.69) | 3.39 (1.22–9.41)^p | 0.33 (0.09–1.16) | 1.07 (0.43–2.66) |
| Duration of use          | 1.00 (0.99–1.01)             | 1.00 (0.99–1.01) | 0.99 (0.98–1.01) | 0.94 (0.90–0.99)^p | 0.99 (0.98–1.00)^p |
| Childhood ADHD subtypes  |                              |                 |                 |               |                |
| Combined subtype         | 4.10 (2.14–7.85)^p           | 7.40 (3.21–17.10)^p | 1.68 (0.88–3.23) | 1.53 (0.72–3.24) | 4.32 (2.14–8.69)^p |
| Full-scale IQ            | 0.97 (0.94–1.00)             | 0.98 (0.95–1.01) | 1.00 (0.97–1.03) | 0.99 (0.96–1.03) | 0.99 (0.96–1.02) |

**ADHD, attention-deficit/hyperactivity disorder; CI, confidence interval**

^p < 0.05

https://doi.org/10.1371/journal.pone.0211873.t005
more than two years had better functioning (self-reported improvement) than those treated for less than two years [76]. These results suggest that pharmacotherapy for ADHD may be most beneficial in reducing comorbidities if it is longer than one year [33], even two years [76]. In the current study, we did not find any differences in comorbidities between those with ADHD who received treatment for longer than one year vs. shorter than one year. However, we found that adults with drug-naïve ADHD were more likely to have sleep disorders than treated ADHD and longer treatment reduced the risk for sleep disorders. This is supported by some studies suggesting that treatment reduces the risk of sleep disorders in ADHD [19, 77]. This finding might be explained by the improvement in life quality with medication treatment, which subsequently reduces the risk of sleep disorders, as evidenced in our prior clinical trial [13].

Our finding that current use of medication increases the risk of anxiety disorder is contradictory to the studies showing that treatment decreased [22, 23, 78] or did not increase the risk of anxiety symptoms [28]. Possible explanations are that medication may cause anxiety symptoms to be diagnosed as anxiety disorders [13]; or that the insufficient response to medication among patients with ADHD comorbid with anxiety may contribute to increased likelihood of current use of medications [79]. These possibilities should be examined in future research with a larger sample of ADHD with or without current medication. Additionally, it is imperative to assess anxiety symptoms and disorders among adults with ADHD who are currently taking medication for treating ADHD. Moreover, the association between shorter duration of treatment and an increased risk of mood disorders is in line with previous research reporting that no treatment or shorter treatment duration increased the risk of substance use [17], which then predicted later risks of mood disorders [11].

Our findings strongly support more instances of psychiatric disorders in adults with ADHD-C than adults with ADHD-I [6, 54]. Specifically, consistent with previous studies, we found that ODD [36, 38, 51, 80], CD [6, 36–39, 52, 53], alcohol use disorder [45], and sleep disorders [17, 47, 48] were more prevalent in adults with childhood ADHD-C than adults with childhood ADHD-I. Our previous research in adolescents has provided strong evidence of high comorbidities of ODD and CD in ADHD-C [20]. Hence, psychiatric comorbid patterns also contribute to the differential diagnosis of these two distinct ADHD subtypes. These findings suggest that more clinical and research attention should be devoted to young adults with childhood ADHD-C, as they are more likely to have disruptive behaviors and disorders, which are highly associated with antisocial behaviors [6, 51], substance use disorders [69], and criminality [51, 81].

**Strengths and limitations**

This study is the first one to examine a wide range of psychiatric comorbidities by using (semi-)structured diagnostic interviews rather than self-reported questionnaires among adults with ADHD and to investigate comprehensively the effects of treatment and treatment duration, as well as childhood ADHD subtypes, on the psychiatric comorbid patterns. Despite this, several limitations merit comments. First, the directionality and causality of the significant findings remain to be determined. Second, although our longitudinal pilot study showed a high correlation between adolescent/mother reports and adult self-reports about the participants’ ADHD symptoms [71], recall bias may still exist. Third, as for treatment effects, this study is not a randomized controlled trial, and treatment in observational studies is usually confounded by indications. Although adults with severe symptoms and impairments are more likely to be treated with medication, which may draw the comparison to the null, we still find some significant results. Lastly, this study may suffer from selection bias during sample
ascertainment because we did not recruit the sample from a representative epidemiological sample. Instead, ADHD adults were recruited from the hospitals through physicians’ referrals and the community through advertisement.

**Conclusion**

Our findings suggest that ADHD often persists into adulthood and is still associated with high psychiatric comorbidity. Treatment with ADHD medications may reduce comorbidity. Moreover, childhood ADHD-C is associated with a greater risk of adult comorbidities than ADHD-I and is one of the significant correlates of adult comorbid conditions. The findings suggest that for adult ADHD, medication treatment should be considered as one of the necessary treatment modalities to prevent the development of psychiatric comorbid conditions. For children with ADHD-C, medication treatment may likewise be helpful to minimize the risks of adverse psychiatric outcomes in adulthood, decreasing social impairment and improving life quality [71].

**Supporting information**

S1 Table. Psychiatric comorbid conditions among ADHD subtypes of adulthood.
(DOC)

S2 Table. Univariate analysis.
(DOC)

**Acknowledgments**

This work was supported by the National Health Research Institute (NHRI-EX100-10008PI, NHRI-EX101-10008PI, NHRI-EX102-10008PI; NHRI-EX103-10008PI), Taiwan. The funders had no role in study design, data collection, decision to publish, or preparation of the manuscript. We would like to express all our thanks to all participants for their participation and to all the anonymous reviewers for their valuable comments.

**Author Contributions**

**Conceptualization:** Fang-Ju Tsai, Wan-Ling Tseng, Susan Shur-Fen Gau.

**Data curation:** Li-Kuang Yang, Susan Shur-Fen Gau.

**Formal analysis:** Wan-Ling Tseng, Susan Shur-Fen Gau.

**Funding acquisition:** Susan Shur-Fen Gau.

**Investigation:** Li-Kuang Yang, Susan Shur-Fen Gau.

**Methodology:** Susan Shur-Fen Gau.

**Project administration:** Susan Shur-Fen Gau.

**Supervision:** Susan Shur-Fen Gau.

**Writing – original draft:** Fang-Ju Tsai, Wan-Ling Tseng.

**Writing – review & editing:** Fang-Ju Tsai, Wan-Ling Tseng.
References

1. Biederman J, Petty CR, O'Connor KB, Hyder LL, Faraone SV (2012) Predictors of persistence in girls with attention deficit hyperactivity disorder: results from an 11-year controlled follow-up study. Acta Psychiatr Scand. 125: 147–156. https://doi.org/10.1111/j.1600-0447.2011.01797.x PMID: 22097933

2. Simon V, Czobor P, Balint S, Meszaros A, Bitter I (2009) Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 194: 204–211. https://doi.org/10.1192/bjp.bp.107.048827 PMID: 19252145

3. Barbarese WJ, Colligan RC, Weaver AL, Voigt RG, Killian JM, Katusic SK (2013) Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. Pediatrics. 131: 637–644. https://doi.org/10.1542/peds.2012-2354 PMID: 23460687

4. Biederman J, Petty CR, Monuteaux MC, Fried R, Byrne D, Mirto T, et al. (2010) Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry. 167: 409–417. https://doi.org/10.1176/appi.ajp.2009.09050736 PMID: 20080964

5. Mannuzza S, Klein RG, Truong NL, Moulton JL 3rd, Roizen ER, Howell KH, et al. (2008) Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry. 165: 604–609. https://doi.org/10.1176/appi.ajp.2008.07091465 PMID: 18381904

6. Pineiro-Dieguez B, Balanza-Martinez V, Garcia-Garcia P, Soler-Lopez B (2016) Psychiatric comorbidity at the time of diagnosis in adults with ADHD: The CAT Study. J Atten Disord. 20: 1066–1075. https://doi.org/10.1177/1087054713518240 PMID: 2446326.

7. Lin YJ, Yang LK, Gau SS (2016) Psychiatric comorbidities of adults with early- and late-onset attention-deficit/hyperactivity disorder. Aust N Z J Psychiatry. 50: 548–556. https://doi.org/10.1177/0004867415609423 PMID: 2460330

8. Rucklidge JJ, Downs-Woolley M, Taylor M, Brown JA, Harrow SE (2016) Psychiatric comorbidities in a New Zealand sample of adults with ADHD. J Atten Disord. 20: 1030–1038. https://doi.org/10.1177/1087054714529457 PMID: 24743977

9. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. (2006) The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 163: 716–723. https://doi.org/10.1176/ajp.2006.163.4.716 PMID: 16585449

10. Biederman J, Petty CR, Dolan C, Hughes S, Mick E, Monuteaux MC, et al. (2008) The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: findings from a controlled 10-year prospective longitudinal follow-up study. Psychol Med. 38: 1027–1036. https://doi.org/10.1017/S0033291713001938 PMID: 18205967

11. Mezina MC, Lewisohn PM, Pettit JW, Seeley JR, Gau JM, Chronis-Tuscano A, et al. (2013) Attention-deficit/hyperactivity disorder in adolescence predicts onset of major depressive disorder through early adulthood. Depress Anxiety. 30: 546–553. https://doi.org/10.1002/da.22082 PMID: 23424020

12. Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, et al. (2008) National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry. 69: 131–140. PMID: 18312048

13. Ni HC, Lin YJ, Gau SS, Huang HC, Yang LK (2017) An open-label, randomized trial of methylphenidate and atomoxetine treatment in adults with ADHD. J Atten Disord. 21: 27–39. https://doi.org/10.1177/1087054714529457 PMID: 23475825

14. Ni HC, Shang CY, Gau SS, Lin YJ, Huang HC, Yang LK (2013) A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 16: 1959–1973. https://doi.org/10.1017/S1461145713000357 PMID: 23672818

15. Shang CY, Yan CG, Lin HY, Tseng WY, Castellanos FX, Gau SS (2016) Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder. Psychol Med. 46: 3173–3185. https://doi.org/10.1017/S0033291716001938 PMID: 27574878

16. Lin YJ, Gau SS (2017) Differential neuropsychological functioning between adolescents with attention-deficit/hyperactivity disorder with and without conduct disorder. J Formos Med Assoc. 116: 946–955. https://doi.org/10.1016/j.jfma.2017.02.009 PMID: 28292624

17. Chang Z, Lichtenstein P, Halldner L, D’Onofrio B, Seriachius E, Fazel S, et al. (2014) Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 55: 878–885. https://doi.org/10.1111/jcpp.12164 PMID: 25158998

18. Purgato M, Cortese S (2014) Does psychostimulant treatment in children with ADHD increase later risk of substance use disorder? Epidemiol Psychiatr Sci. 23: 133–135. https://doi.org/10.1017/S204579601400146 PMID: 24642169
19. Groenman AP, Oosterlaan J, Rommelse N, Franke B, Greven CU, Hoekstra PJ, et al. (2013) Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. Br J Psychiatry. 203: 112–119. https://doi.org/10.1192/bjp.bp.112.124784 PMID: 23846996

20. Gau SS, Ni HC, Shang CY, Soong WT, Wu YY, Lin LY, et al. (2010) Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder. Aust N Z J Psychiatry. 44: 135–143. https://doi.org/10.3109/00048670903282733 PMID: 20113302

21. Daviss WB, Birmaher B, Diler RS, Mintz J (2008) Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression? J Child Adolesc Psychopharmacol. 18: 257–264. https://doi.org/10.1089/cap.2007.0100 PMID: 18582180

22. Gurkan K, Bilgic A, Turkoglu S, Kilic BG, Aysev A, Uslu R (2010) Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment. J Psychopharmacol. 24: 1810–1818. https://doi.org/10.1177/0269881109348172 PMID: 19939861

23. Golubchik P, Sever J, Weizman A (2014) Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia. Int Clin Psychopharmacol. 29: 212–215. https://doi.org/10.1097/YIC.000000000000029 PMID: 24448460

24. Dukarm CP (2005) Bulimia nervosa and attention deficit hyperactivity disorder: a possible role for stimulant medication. J Womens Health (Larchmt). 14: 345–350. https://doi.org/10.1089/jwh.2005.14.345 PMID: 15916509

25. Drimmer EJ (2003) Methylphenidate treatment of bulimia nervosa with and without attention-deficit disorder: three case reports. Nutrition. 19: 76–77. PMID: 12507648

26. Kollins SH (2008) A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Curr Med Res Opin. 24:1345–1357. https://doi.org/10.1185/030079908X280707 PMID: 18384709

27. Vansickel AR, Stoops WW, Glaser PE, Poole MM, Rush CR (2011) Methylphenidate increases cigarette smoking in participants with ADHD. Psychopharmacology (Berl). 218: 381–390. https://doi.org/10.1007/s00213-011-2328-y PMID: 21590284

28. Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, et al. (2009) The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 48: 484–500. https://doi.org/10.1097/CHI.0b013e31819c23d0 PMID: 19318991

29. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV (2008) Stimulant therapy and risk for subsequent substance use disorders in males with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 165: 597–603. https://doi.org/10.1176/appi.ajp.2007.07091486 PMID: 18316421

30. Mannuzza S, Klein RG, Moulton JL 3rd (2003) Does stimulant treatment place children at risk for adult substance abuse? A controlled, prospective follow-up study. J Child Adolesc Psychopharmacol. 13: 273–282. https://doi.org/10.1089/10445600332572606 PMID: 14642015

31. Winters KC, Lee S, Botzet A, Fahnhorst T, Realmuto GM, August GJ (2011) A prospective examination of the association of stimulant medication history and drug use outcomes among community samples of ADHD youths. J Child Adolesc Subst Abuse. 20: 314–329. https://doi.org/10.1080/1067828X.2011.598834 PMID: 22582022

32. Humphreys KL, Eng T, Lee SS (2013) Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry. 70: 740–749. https://doi.org/10.1001/jamapsyc hiatry.2013.1273 PMID: 23754458

33. Staikova E, Marks DJ, Miller CJ, Newcorn JH, Halperin JM (2010) Childhood stimulant treatment and teen depression: is there a relationship? J Child Adolesc Psychopharmacol. 20: 387–399. https://doi.org/10.1089/cap.2009.0107 PMID: 20973709

34. Sheng CY, Sheng C, Yang LK, Chou TL, Gau SS (2018) Differential brain activations in adult attention-deficit/hyperactivity disorder subtypes: a counting Stroop functional MRI study. Brain Imaging Behav. 12: 882–890. https://doi.org/10.1007/s11682-017-9749-0 PMID: 28699075

35. Chiang HL, Huang LW, Gau SS, Shang CY (2013) Associations of symptoms and subtypes of attention-deficit hyperactivity disorder with visuospatial planning ability in youth. Res Dev Disabil. 34: 2986–2995. https://doi.org/10.1016/j.ridd.2013.06.020 PMID: 23811280

36. Yuce M, Zoroglu SS, Ceylan MF, Kandemir H, Karabekiroglu K (2013) Psychiatric comorbidity distribution and diversities in children and adolescents with attention deficit/hyperactivity disorder: a study from Turkey. Neuropsychiatr Dis Treat. 9: 1791–1799. https://doi.org/10.2147/NDT.S54283 PMID: 24265552
37. Acosta MT, Castellanos FX, Bolton KL, Balog JZ, Eigens P, Nee L, et al. (2008) Latent class subtyping of attention-deficit/hyperactivity disorder and comorbid conditions. J Am Acad Child Adolesc Psychiatry. 47: 797–807. https://doi.org/10.1097/CHI.0b013e318173f70b PMID: 18520958

38. Oner O, Oner P, Cop E, Munir KM (2012) Characteristics of DSM-IV attention deficit hyperactivity disorder combined and predominantly inattentive subtypes in a Turkish clinical sample. Child Psychiatry Hum Dev. 43: 523–532. https://doi.org/10.1007/s10578-012-0281-6 PMID: 22249362

39. Grizenko N, Paci M, Jobber R (2010) Is the inattentive subtype of ADHD different from the combined/hyperactive subtype? J Atten Disord. 13: 649–657. https://doi.org/10.1177/1087054709347200 PMID: 19767592

40. Sciberras E, Lyczek K, Efren D, Mensah F, Gerner B, Hiscock H (2014) Anxiety in Children With Attention-Deficit/Hyperactivity Disorder. Pediatrics. 133: 801–808. https://doi.org/10.1542/peds.2013-3686 PMID: 24753534

41. Levy F, Hay DA, Bennett KS, McStephen M (2005) Gender differences in ADHD subtype comorbidity. J Am Acad Child Adolesc Psychiatry. 44: 368–376. https://doi.org/10.1097/01.chi.0000153232.64968.c1 PMID: 15782084

42. Chronis-Tuscano A, Molina BS, Pelham WE, Applegate B, Dahlke A, Overmyer M, et al. (2010) Very early predictors of adolescent depression and suicide attempts in children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 67: 1044–1051. https://doi.org/10.1001/archgenpsychiatry.2010.127 PMID: 20921120

43. Donfrancesco R, Di Trani M, Andriola E, Leone D, Torrioli MG, Passarelli F, et al. (2017) Bipolar disorder in children with ADHD: a clinical sample study. J Atten Disord. 21: 715–720. https://doi.org/10.1177/1087054714539999 PMID: 25015582

44. Sivakumar T, Agarwal V, Sithole Y (2013) Comorbidity of attention-deficit/hyperactivity disorder and bipolar disorder in North Indian clinic children and adolescents. Asian J Psychiatr. 6: 235–242. https://doi.org/10.1016/j.ajp.2012.12.011 PMID: 23642982

45. Tamm L, Adinoff B, Nakonezny PA, Winhusen T, Rigg P (2012) Attention-deficit/hyperactivity disorder subtypes in adolescents with comorbid substance-use disorder. Am J Drug Alcohol Abuse. 38: 93–100. https://doi.org/10.3109/00952990.2011.600395 PMID: 21834613

46. Elkins JJ, McGue M, Iacono WG (2007) Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. Arch Gen Psychiatry. 64: 1145–1152. https://doi.org/10.1001/archpsyc.64.11.1145 PMID: 17909126

47. Mayes SD, Calhoun SL, Bixler EO, Vgontzas AN, Mahr F, Hillwig-Garcia J, et al. (2009) ADHD subtypes and comorbid anxiety, depression, and oppositional-defiant disorder: differences in sleep problems. J Pediatr Psychol. 34: 328–337. https://doi.org/10.1093/jpepsy/jsn083 PMID: 18676503

48. Chiang HL, Gau SS, Ni HC, Chiu YN, Shang CY, Wu YY, et al. (2010) Association between symptoms and subtypes of attention-deficit hyperactivity disorder and sleep problems/disorders. J Sleep Res. 19: 535–545. https://doi.org/10.1111/j.1365-2869.2010.00832.x PMID: 20408926

49. Bleck JR, DeBate RD, Olivoraida R (2015) The comorbidity of ADHD and eating disorders in a nationally representative sample. J Behav Health Serv Res. 42: 437–451. https://doi.org/10.1007/s11414-014-9422-y PMID: 25007864

50. Adewuya AO, Famuyiwa OO (2007) Attention deficit hyperactivity disorder among Nigerian primary school children: prevalence and co-morbid conditions. Eur Child Adolesc Psychiatry. 16: 10–15. https://doi.org/10.1007/s00787-006-0569-9 PMID: 17136303

51. Murphy KR, Barkley RA, Bush T (2002) Young adults with attention deficit hyperactivity disorder: subtype differences in comorbidity, educational, and clinical history. J Nerv Ment Dis. 190: 147–157. PMID: 11923649

52. Cumyn L, French L, Hechtman L (2009) Comorbidity in adults with attention-deficit/hyperactivity disorder. Can J Psychiatry. 54: 673–683. https://doi.org/10.1177/07067437095401004 PMID: 19835674

53. Wilems TE, Biederman J, Faraone SV, Martelon M, Westerberg D, Spencer TJ (2009) Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD. J Clin Psychiatry. 70: 1557–1562. https://doi.org/10.4088/JCP.08m047566 PMID: 20031097

54. Soendergaard HM, Thomsen PH, Pedersen E, Pedersen P, Poulsen AE, Winther L, et al. (2016) Associations of age, gender, and subtypes with ADHD symptoms and related comorbidity in a Danish sample of clinically referred adults. J Atten Disord. 20: 925–933. https://doi.org/10.1177/1087054715617544 PMID: 24412968

55. Sobanski E, Bruggemann D, Alm B, Kern S, Philipsen A, Schmalzried H, et al. (2008) Subtype differences in adults with attention-deficit/hyperactivity disorder (ADHD) with regard to ADHD-symptoms, psychiatric comorbidity and psychosocial adjustment. Eur Psychiatry. 23: 142–149. https://doi.org/10.1016/j.eurpsy.2007.09.007 PMID: 18024089
56. Gau SS, Kessler RC, Tseng WL, Wu YY, Chiu YN, Yeh CB, et al. (2007) Association between sleep problems and symptoms of attention-deficit/hyperactivity disorder in young adults. Sleep. 30: 195–201. PMID: 17326545

57. Caci H, Bouchez J, Bayle FJ (2009) Inattentive symptoms of ADHD are related to evening orientation. J Atten Disord. 13: 36–41. https://doi.org/10.1177/1087054708320439 PMID: 19387003

58. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M (1998) Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry. 155: 493–498. https://doi.org/10.1176/ajp.155.4.493 PMID: 9545994

59. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, et al. (2005) The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 35: 245–256. PMID: 15841682

60. Yeh CB, Gau SS, Kessler RC, Wu YY (2008) Psychometric properties of the Chinese version of the adult ADHD self-report scale. Int J Methods Psychiatr Res. 17: 45–54. https://doi.org/10.1002/mpr.241 PMID: 18286465

61. Conners CK, Erhardt D., & Sparrow E. Conners’ adult ADHD rating scales (CAARS). New York, NY: Multi-Health Systems. 1999.

62. Chang LR, Chiu YN, Wu YY, Gau SS (2013) Father’s parenting and father-child relationship among children and adolescents with attention-deficit/hyperactivity disorder. Compr Psychiatry. 54: 128–140. https://doi.org/10.1016/j.comppsych.2012.07.008 PMID: 22985803

63. Gau SS, Chong MY, Chen TH, Cheng AT (2005) A 3-year panel study of mental disorders among adolescents in Taiwan. Am J Psychiatry. 162: 1344–1350. https://doi.org/10.1176/appi.ajp.162.7.1344 PMID: 15994718

64. Gau SF, Soong WT (1999) Psychiatric comorbidity of adolescents with sleep terrors or sleepwalking: a case-control study. Aust N Z J Psychiatry. 33: 734–739. https://doi.org/10.1080/j.1440-1614.1999.00610.x PMID: 10544999

65. Chiang HL, Chen YJ, Shang CY, Tseng WI, Gau SS (2016) Different neural substrates for executive functions in youths with ADHD: a diffusion spectrum imaging tractography study. Psychol Med. 46: 1225–1238. https://doi.org/10.1017/S0033291715002767 PMID: 26744120

66. Gau SS, Tseng WL, Tseng WY, Wu YH, Lo YC (2015) Association between microstructural integrity of frontostratal tracts and school functioning: ADHD symptoms and executive function as mediators. Psychol Med. 45: 529–543. https://doi.org/10.1017/S0033291714001664 PMID: 25075643

67. Gau SS, Huang WL (2014) Rapid visual information processing as a cognitive endophenotype of attention deficit hyperactivity disorder. Psychol Med. 44: 435–446. https://doi.org/10.1017/S0033291713000640 PMID: 23561037

68. Lin YJ, Chen WJ, Gau SS (2014) Neuropsychological functions among adolescents with persistent, subsyndromal and remitted attention deficit hyperactivity disorder. Psychol Med. 44: 1765–1777. https://doi.org/10.1017/S0033291713002390 PMID: 24074179

69. Gau SS, Chong MY, Yang P, Yen CF, Liang KY, Cheng AT (2007) Psychiatric and psychosocial predictors of substance use disorders among adolescents: longitudinal study. Br J Psychiatry. 190: 42–48. https://doi.org/10.1192/bjp.bp.106.022871 PMID: 17197655

70. Gau SS, Chang JP (2013) Maternal parenting styles and mother-child relationship among adolescents with and without persistent attention-deficit/hyperactivity disorder. Res Dev Disabil. 34: 1581–1594. https://doi.org/10.1016/j.ridd.2013.02.002 PMID: 23475008

71. Lin YJ, Lo KW, Yang LK, Gau SS (2015) Validation of DSM-5 age-of-onset criterion of attention deficit/hyperactivity disorder (ADHD) in adults: Comparison of life quality, functional impairment, and family function. Res Dev Disabil. 47: 48–60. https://doi.org/10.1016/j.ridd.2015.07.026 PMID: 26318976

72. Merikangas KR, Mehta RL, Molnar BE, Walters EE, Swendsen JD, Aguilar-Gaxiola S, et al. (1998) Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav. 23: 893–907. PMID: 9801724

73. Endicott J, Spitzer RL (1978) A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry. 35: 837–844. PMID: 678037

74. Ní HC, Gau SS (2015) Co-occurrence of attention-deficit/hyperactivity disorder symptoms with other psychopathology in young adults: parenting style as a moderator. Compr Psychiatry. 57: 85–96. https://doi.org/10.1016/j.comppsych.2014.11.002 PMID: 25465651

75. Klein RG, Mannuzza S, Olazagasti MA, Roizen E, Hutchison JA, Lashua EC, et al. (2012) Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry. 69: 1295–1303. https://doi.org/10.1001/archgenpsychiatry.2012.271 PMID: 23070149

76. Lensing MB, Zeiner P, Sandvik L, Opjordsmoen S (2013) Four-year outcome in psychopharmacologically treated adults with attention-deficit/hyperactivity disorder: a questionnaire survey. J Clin Psychiatry. 74:e87–e93. https://doi.org/10.4088/JCP.12m07714 PMID: 23419235
77. Willcutt EG, Nigg JT, Pennington BF, Solanto MV, Rohde LA, Tannock R, et al. (2012) Validity of DSM-IV attention deficit/hyperactivity disorder symptom dimensions and subtypes. J Abnorm Psychol. 121: 991–1010. https://doi.org/10.1037/a0027347 PMID: 22612200

78. Golubchik P, Golubchik L, Sever JM, Weizman A (2014) The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety. Int Clin Psychopharmacol. 29: 274–278. https://doi.org/10.1097/YIC.000000000000034 PMID: 24743562

79. Moshe K, Karni A, Tiross E (2012) Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial. Atten Defic Hyperact Disord. 4: 153–158. https://doi.org/10.1007/s12402-012-0078-2 PMID: 22622628

80. Yang P, Jong YJ, Hsu HY, Tsai JH (2007) Psychiatric features and parenting stress profiles of subtypes of attention-deficit/hyperactivity disorder: results from a clinically referred Taiwanese sample. J Dev Behav Pediatr. 28: 369–375. https://doi.org/10.1097/DBP.0b013e3181131f8e PMID: 18049319

81. Mannuzza S, Klein RG, Moulton JL 3rd (2008) Lifetime criminality among boys with attention deficit hyperactivity disorder: a prospective follow-up study into adulthood using official arrest records. Psychiatry Res. 160: 237–246. https://doi.org/10.1016/j.psychres.2007.11.003 PMID: 18707766